Document Detail


Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
MedLine Citation:
PMID:  17578828     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and is important in monitoring the disease course and NET treatment. AIM OF THE STUDY: Usefulness of suppression test of CgA secretion with octreotide in diagnosis and predicting the therapy outcome in NET patients. MATERIAL AND METHODS: The study included 32 patients with NET of gastrointestinal tract, lung and of unknown origin. CgA level in blood plasma on fasting, before and 30, 60, 90 and 120 minutes after subcutaneous administration of 100 mug octreotide, was determined in all patients. The subjects were divided into two subgroups with relation to CgA level and to the results of somatostatin receptor scintigraphy (SRS). RESULTS: Statistically significant CgA decrease after octreotide administration in all study time points and positive results of SRS were found in the patients with the elevated CgA level. No statistically significant decrease of CgA level after octreotide was found in the group with normal CgA levels. In this group, 13 patients had a negative result of SRS, and somatostatin receptors expression was found in one patient. Tolerance of somatostatin analogs (SSA) therapy was very good. CONCLUSIONS: Octreotide suppression test with CgA level assessment in NET patients is a simple, straightforward examination, providing information on the predicted response to the applied SSA and the data on initial clinical tolerance of those agents. This examination can also be a screening test useful in planning the treatment with SSA in patients with NET.
Authors:
Beata Kos-Kudła; Anna Zemczak; Wanda Foltyn; Bogdan Marek; Janusz Strzelczyk; Aleksandra Telega; Wojciech Zajecki; Tomasz Legaszewski; Beata Jurecka-Lubieniecka
Related Documents :
1713218 - Plasma free triiodothyronine response to thyrotropin-releasing hormone to predict the r...
175528 - Investigations on the level of circulating eosinophils throughout a 24 hour period in p...
3098458 - Growth hormone responses to grf 1-29 in patients with primary hypothyroidism before and...
3576118 - Highly sensitive assays of serum-thyrotropin in the diagnosis of hyperthyroidism: asses...
2594748 - Dental x-ray status of patients admitted for total hip replacement.
19670118 - Diagnosis and treatment of spontaneous pneumomediastinum.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Endokrynologia Polska     Volume:  58     ISSN:  0423-104X     ISO Abbreviation:  Endokrynol Pol     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2007-06-20     Completed Date:  2008-02-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370674     Medline TA:  Endokrynol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  123-9     Citation Subset:  IM    
Affiliation:
Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Zabrze. bkoskudla@slam.katowice.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents, Hormonal / therapeutic use
Chromogranin A / blood*
Female
Gastrointestinal Neoplasms / blood,  diagnosis
Humans
Injections, Subcutaneous
Lung Neoplasms / blood,  diagnosis
Male
Neuroendocrine Tumors / blood*,  diagnosis*
Octreotide / diagnostic use*
Organotechnetium Compounds / diagnostic use
Pancreatic Neoplasms / blood,  diagnosis
Pilot Projects
Predictive Value of Tests
Radiopharmaceuticals / diagnostic use
Receptors, Somatostatin / analysis
Somatostatin / analogs & derivatives,  diagnostic use,  therapeutic use
Thyroid Neoplasms / blood,  diagnosis
Tumor Markers, Biological / blood*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Chromogranin A; 0/Organotechnetium Compounds; 0/Radiopharmaceuticals; 0/Receptors, Somatostatin; 0/Tumor Markers, Biological; 0/technetium 99m EDDA-HYNIC-Tyr(3)-octreotide; 51110-01-1/Somatostatin; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
Next Document:  The influence of bariatric surgery on calcium homeostasis and biochemical markers of bone turnover i...